Simulocity Expands Internationally, Virtualizing Top Pharmas in Switzerland, Denmark, Germany, Italy, and Japan benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Let s Talk Interactive Sees Successful Q1 as a Leading Telehealth Solutions Provider
Let s Talk Interactive starts off 2021 with an award as a top 10 leading telehealth solution provider, the implementation of a new video platform, and a key hire.
News provided by
Share this article
Share this article
CHARLOTTE, N.C., May 4, 2021 /PRNewswire/ Let s Talk Interactive, Inc., a leader in customizable telehealth solutions, reports a successful first quarter with ambitious moves to capitalize on soaring demand for telehealth solutions, spurred by patients and providers seeking safe and convenient remote healthcare during the COVID-19 pandemic.
Let s Talk Interactive (LTI) provides HIPAA-compliant telemedicine software and hardware solutions to hospital/healthcare facilities, education systems, physician practices and other organizations.
Orlando, Florida (Newsfile Corp. - April 30, 2021) - Simulocity's partnership with PRMA is one of a myriad of virtual platforms for businesses that they have developed for industry leaders around the
EMulate Therapeutics Featured in Healthcare Tech Outlook Article titled Ushering in a New Era in Non-Invasive Cancer Therapy tennesseedaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tennesseedaily.com Daily Mail and Mail on Sunday newspapers.
An excerpt from the article can be found below: EMulate Therapeutics Voyager ulRFE® system. It is a non-invasive, non-thermal, non-ionizing, non-sterile medical device, the first of many product expressions of the company s underlying ulRFE platform technology. Showing promise in preclinical and clinical trials, the EMulate Therapeutics Voyager has potential treatment applications in a wide range of diseases, including cancer, chronic pain, and inflammation, among others. EMulate Therapeutics Voyager device is currently being evaluated to treat glioblastoma multiforme (GBM) brain tumors in human clinical trials. The ultimate goal of EMulate Therapeutics is to deliver beneficial effects that would improve life for humans, animals, and other biological organisms without the need for chemicals that may have harmful side effects, says Chris E. Rivera, President and CEO of EMulate Therapeutics.